Bioxytran Company Description

Bioxytran, Inc., a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans.

The company’s lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing.

It is also developing ProLectin-Rx, a polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin for treatment of mild to moderate cases of Covid-19.

The company was founded in 2008 and is headquartered in Needham, Massachusetts.

Bioxytran, Inc.

Country	United States
Founded	2008
Industry	Biotechnology
Sector	Healthcare
Employees	3
CEO	David Platt

Contact Details

Address: 75 2nd Avenue Needham, Nevada 02494 United States
Phone	617 454 1199
Website	bioxytraninc.com

Stock Details

Ticker Symbol	BIXT
Exchange	OTCMKTS
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
ISIN Number	US09075D1028
SIC Code	2836

Key Executives

Name	Position
Dr. David Platt Ph.D.	Chairman, Chief Executive Officer and President
Ola Soderquist C.M.A., C.P.A., CM&AA, CMA, CPA, M.B.A.	Chief Financial Officer, Treasurer and Secretary
Michael Sheikh B.S.	Chief Communication Officer